Key Pharmaceuticals, Inc.

Syntex (u.s.a.) Inc.

Charles H Hsiao

John S Kent

Alec D Keith

Chi T Chou

A controlled release potassium chloride tablet is disclosed which is comprised of potassium chloride crystals having a mesh size of about 30 to about 50 mesh which are coated with a coating material comprised of ethylcellulose and hydroxypropylcellulose. The coated crystals form micro pellets which then can be compressed into tablets. The tablets disintegrate rapidly in an aqueous environment thus assuring a more uniform dissolution of the active component as compared with other types of controlled release potassium chloride dosage formulations. The distribution of the potassium chloride micro pellets over a wide surface area in the gastrointestinal mucosa aids in reducing the risk of gastrointestinal lesions. The formation of the coated micro pellets which disperse quickly upon contact with aqueous environment allow for the repeated chronic oral administration of a relatively large dose of potassium chloride (20 mEq).

Controlled release potassium chloride

A controlled release tablet for once-daily oral administration of about 500-1200 mg of naproxen or naproxen sodium, said tablet comprising a homogeneous matrix comprising about 4-9 weight percent of hydroxypropyl methylcellulose having a number average molecular weight in the range of from about 80,000 to about 130,000, about 81-96 weight percent naproxen or naproxen sodium, and 0.1 to about 2 weight percent of a pharmaceutically acceptable lubricating agent, and optionally including a pharmaceutically acceptable coating.

Controlled release naproxen and naproxen sodium tablets

A minipellet dosage form of prednisone or prednisolone, resistant to attack by saliva but readily dissolvable in gastric juice, which comprises a mixture of prednisone or prednisolone and polyvinylpyrrolidone coated onto a nonpareil seed, and further coated with a layer of dimethylaminoethyl and methyl methacrylate copolymer.

Minipellets

A sustained release quindine dosage form is made from a plurality of pellets. Each pellet includes a quinidine-containing coating over a nonpareil seed, with a further coating of about 5 to about 15% by weight of a mixture of about 1.5 to about 9 parts by weight ethylcellulose to about 1 part by weight hydroxypropylcellulose.

Sustained release quinidine dosage form

A controlled release tablet for once-daily oral administration of about 500-1200 mg of naproxen or naproxen sodium, said tablet being a homogeneous matrix comprising about 4-9 weight percent of hydroxypropylmethylcellulose having a number average molecular weight in the range of from about 80,000 to about 130,000, about 81-96 weight percent naproxen or naproxen sodium, 0.1 to about 2 weight percent of a pharmacetucailly acceptable lubricating agent, and 0 to about 8 weight percent of other pharmaceutically acceptable excipients.

A method of providing a patient suffering from cardiac arrhythmia with a sustained dosage of propranolol over a prolonged period of time comprises orally administering to the patient a tablet consisting essentially of a therapeutically effective amount of propranolol to provide a sustained release thereof over a prolonged period of time which is contained in compressed granules having from about 0.1 to about 10 parts by weight hydroxypropyl methylcellulose and about one part by weight hydroxypropyl cellulose and a lubricant for the compressed granules.

Sustained release propranolol tablet

A tablet, which readily disintegrates in gastric fluid to give aspirin crystals coated with a polymeric film preventing the aspirin crystals from contacting the stomach wall but not preventing access of gastric fluid to the aspirin contained within the polymer film, which consists of a plurality of aspirin crystals 20-60 mesh in size coated with about 3-10% by weight of a polymeric mixture comprising from about 1.5 to about 15 parts by weight ethylcellulose and about one part by weight hydroxypropylcellulose; a compression aid; a disintegrant; and a tableting aid.

Aspirin tablet

A sustained release aspirin dosage form permits the continuous delivery of aspirin into the gastrointestinal tract for a period of at least eight hours. The sustained release aspirin dosage form comprises a plurality of polymerically coated aspirin crystals each of which comprises an aspirin seed. The majority of aspirin seeds have a mesh size of from about 30 to about 60 mesh. Each of the aspirin seeds is individually coated with a polymeric mixture, which comprises from about 1.5 to about 15 parts by weight ethylcellulose and about one part by weight hydroxypropylcellulose.

Sustained release aspirin

A sustained release oral dosage form is provided comprising a tablet core containing a pharmaceutically effective amount of quinidine. The tablet core is coated with a sustained release polymeric coating which contains about 5 to about 20 percent by weight polyethylene glycol component having a molecular weight of from about 500 to about 200, and from about 80 to 95 percent by weight polyvinylalcohol component. The polyvinylalcohol component comprises from about one to about ten parts by weight of a partially hydrolyzed polyvinylalcohol subcomponent having a degree of hydrolysis of from about 75 to about 92 percent and about one part by weight of a substantially completely hydrolyzed polyvinylalcohol subcomponent having a degree of hydrolysis in excess of 95%.

Growing community of inventors

Cooper City, FL, United States of America

Charles H Hsiao